All Stories

  1. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer

    Article • Proceedings of the National Academy of Sciences, January 2024, Proceedings of the National Academy of Sciences

    Dr Josie Ursini-Siegel

  2. p66ShcA Promotes Breast Cancer Plasticity by Inducing an Epithelial-to-Mesenchymal Transition

    Article • Molecular and Cellular Biology, July 2014, ASM Journals

    Dr Josie Ursini-Siegel

  3. Peripheral blood cells inform on the presence of breast cancer: A population‐based case–control study

    Article • International Journal of Cancer, June 2014, Wiley

    Dr Josie Ursini-Siegel

  4. The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner

    Article • Oncogene, May 2014, Springer Science + Business Media

    Dr Josie Ursini-Siegel

  5. The ShcA PTB Domain Functions as a Biological Sensor of Phosphotyrosine Signaling during Breast Cancer Progression

    Article • Cancer Research, May 2013, American Association for Cancer Research (AACR)

    Dr Josie Ursini-Siegel

  6. It takes two to tango in the microenvironment!

    Article • March 2013, Springer Science + Business Media

    Dr Josie Ursini-Siegel

  7. Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer

    Article • March 2013, Springer Science + Business Media

    Dr Josie Ursini-Siegel

  8. A complex containing LPP and  -actinin mediates TGF -induced migration and invasion of ErbB2-expressing breast cancer cells

    Article • Journal of Cell Science, February 2013, The Company of Biologists

    Dr Josie Ursini-Siegel

  9. Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?

    Article • Frontiers in Oncology, January 2013, Frontiers

    Dr Josie Ursini-Siegel

  10. Abstract P1-05-22: Breast cancer cells that undergo an Epithelial-to-Mesenchymal transition co-opt LPP, a regulator of mesenchymal cell migration and invasion.

    Article • Cancer Research, December 2012, American Association for Cancer Research (AACR)

    Dr Josie Ursini-Siegel

  11. The ShcA SH2 domain engages a 14-3-3/PI3′K signaling complex and promotes breast cancer cell survival

    Article • Oncogene, January 2012, Springer Science + Business Media

    Dr Josie Ursini-Siegel

  12. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling

    Article • Proceedings of the National Academy of Sciences, September 2011, Proceedings of the National Academy of Sciences

    Dr Josie Ursini-Siegel

  13. Beyond immune surveillance: Stat1 limits tumor growth in a cell-autonomous fashion

    Article • Cell Cycle, May 2011, Taylor & Francis

    Dr Josie Ursini-Siegel

  14. Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response

    Article • Cancer Research, October 2010, American Association for Cancer Research (AACR)

    Dr Josie Ursini-Siegel

  15. The ShcA adaptor protein is a critical regulator of breast cancer progression

    Article • Cell Cycle, July 2008, Taylor & Francis

    Dr Josie Ursini-Siegel

  16. ShcA signalling is essential for tumour progression in mouse models of human breast cancer

    Article • The EMBO Journal, February 2008, Springer Science + Business Media

    Dr Josie Ursini-Siegel

  17. Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development

    Article • Molecular and Cellular Biology, July 2007, ASM Journals

    Dr Josie Ursini-Siegel

  18. Insights from transgenic mouse models of ERBB2-induced breast cancer

    Article • Nature Reviews Cancer, April 2007, Springer Science + Business Media

    Dr Josie Ursini-Siegel

  19. TRAIL/Apo-2 Ligand Induces Primary Plasma Cell Apoptosis

    Article • The Journal of Immunology, November 2002, The American Association of Immunologists

    Dr Josie Ursini-Siegel

  20. CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells

    Article • Immunity, August 2002, Elsevier

    Dr Josie Ursini-Siegel, Dr Kai-Michael Toellner